Refractory Multiple Myeloma: 1500 Clinical Trials, Page 148 of 150

Hide Studies Not Open or Pending


Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Condition(s):Age Range ≥16 Years, Gender Unlimited; Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma; Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed; At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin’s and Non-Hodgkin’s Lymphoma; ECOG Physical Status Score is 0-3; The Researchers Judged That Life Expectancy Was at Least Three Months; Understand and Voluntarily Sign Written Informed ConsentLast Updated:September 20, 2021Unknown status


Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Condition(s):Non Hodgkin Lymphoma; Richter Transformation; Multiple Myeloma; T-cell-prolymphocytic Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myeodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Chronic Myelomonocytic Leukemia-2; Myelodysplastic Neoplasm in Blast PhaseLast Updated:March 29, 2023Recruiting

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.